Catalent Inc. (CTLT): Price and Financial Metrics

Catalent Inc. (CTLT): $46.74

1.51 (-3.13%)

POWR Rating

Component Grades








CTLT Price/Volume Stats

Current price $46.74 52-week high $82.73
Prev. close $48.25 52-week low $31.45
Day low $46.62 Volume 647,749
Day high $47.87 Avg. volume 3,339,439
50-day MA $47.10 Dividend yield N/A
200-day MA $50.42 Market Cap 8.43B

CTLT Stock Price Chart Interactive Chart >


  • Value is the dimension where CTLT ranks best; there it ranks ahead of 41.59% of US stocks.
  • CTLT's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • CTLT ranks lowest in Sentiment; there it ranks in the 5th percentile.

CTLT Stock Summary

  • With a market capitalization of $8,507,023,458, CATALENT INC has a greater market value than 82.42% of US stocks.
  • With a price/earnings ratio of 405.1, CATALENT INC P/E ratio is greater than that of about 98.51% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for CATALENT INC is higher than 95.38% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to CTLT, based on their financial statements, market capitalization, and price volatility, are TTEC, TRU, FOXA, SP, and NPO.
  • Visit CTLT's SEC page to see the company's official filings. To visit the company's web site, go to

CTLT Valuation Summary

  • CTLT's price/sales ratio is 1.9; this is 0% higher than that of the median Healthcare stock.
  • CTLT's EV/EBIT ratio has moved up 44.7 over the prior 111 months.

Below are key valuation metrics over time for CTLT.

Stock Date P/S P/B P/E EV/EBIT
CTLT 2023-09-18 1.9 1.8 405.1 72.0
CTLT 2023-09-15 2.0 1.9 422.0 74.0
CTLT 2023-09-14 2.0 1.9 426.4 74.5
CTLT 2023-09-13 2.0 1.9 419.1 73.6
CTLT 2023-09-12 1.9 1.9 414.5 73.1
CTLT 2023-09-11 2.0 1.9 420.8 73.8

CTLT Growth Metrics

    Its year over year revenue growth rate is now at 25.17%.
  • Its 4 year net cashflow from operations growth rate is now at 52.44%.
  • Its 5 year net cashflow from operations growth rate is now at 52.44%.
Over the past 34 months, CTLT's revenue has gone up $1,884,600,000.

The table below shows CTLT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 4,757 329 409
2022-09-30 4,825 184 421
2022-06-30 4,828 439 503
2022-03-31 4,703.2 504.3 486.9
2021-12-31 4,483.5 441.3 563
2021-09-30 4,177.3 446.3 546.6

CTLT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTLT has a Quality Grade of C, ranking ahead of 31.5% of graded US stocks.
  • CTLT's asset turnover comes in at 0.461 -- ranking 93rd of 682 Pharmaceutical Products stocks.
  • INSM, SPPI, and HSKA are the stocks whose asset turnover ratios are most correlated with CTLT.

The table below shows CTLT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.461 0.342 0.125
2021-06-30 0.469 0.338 0.131
2021-03-31 0.459 0.332 0.129
2020-12-31 0.447 0.323 0.086
2020-09-30 0.451 0.322 0.082
2020-06-30 0.456 0.318 0.073

Catalent Inc. (CTLT) Company Bio

Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologicsgene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue. (Source:Wikipedia)

CTLT Latest News Stream

Event/Time News Detail
Loading, please wait...

CTLT Latest Social Stream

Loading social stream, please wait...

View Full CTLT Social Stream

Latest CTLT News From Around the Web

Below are the latest news stories about CATALENT INC that investors may wish to consider to help them evaluate CTLT as an investment opportunity.

Catalent Appoints David McErlane as Biologics Segment Leader

SOMERSET, N.J., September 18, 2023--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023.

Yahoo | September 18, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

SOMERSET, N.J., September 15, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, on September 14, 2023, it received a notice (the "NYSE Notice") from the New York Stock Exchange (the "NYSE") that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Ma

Yahoo | September 15, 2023

Is Catalent Inc (CTLT) Set to Underperform? Analyzing the Factors Limiting Growth

Unraveling the Financial Metrics of Catalent Inc (CTLT)

Yahoo | September 11, 2023

Is Catalent (CTLT) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

Unpacking the Risks and Rewards of Investing in Catalent (CTLT)

Yahoo | September 11, 2023

3 Debt-Ridden S&P 500 Stocks to Sell Before It’s Too Late

S&P 500 companies collectively saw second-quarter earnings fall by 4% over last year.

Will Ashworth on InvestorPlace | September 7, 2023

Read More 'CTLT' Stories Here

CTLT Price Returns

1-mo 5.25%
3-mo 6.08%
6-mo -27.28%
1-year -43.79%
3-year -45.37%
5-year 9.59%
YTD 3.84%
2022 -64.84%
2021 23.02%
2020 84.85%
2019 80.56%
2018 -24.10%

Continue Researching CTLT

Here are a few links from around the web to help you further your research on Catalent Inc's stock as an investment opportunity:

Catalent Inc (CTLT) Stock Price | Nasdaq
Catalent Inc (CTLT) Stock Quote, History and News - Yahoo Finance
Catalent Inc (CTLT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!